In conclusion, procedural dobutamine infusion in patients undergoing MitraClip implantation is reasonably safe, leading to low rates of AM, and is not associated with induced ischemia, increased mortality, and rehospitalization for heart failure at follow-up. Larger studies are needed to confirm our findings and to identify the optimal management strategy in this group of patients.
Procedural management of patients with advanced heart failure undergoing MitraClip implantation (from the GRASP registry)
CAPODANNO, DAVIDE FRANCESCO MARIA;CAPRANZANO P;TAMBURINO, Corrado
2017-01-01
Abstract
In conclusion, procedural dobutamine infusion in patients undergoing MitraClip implantation is reasonably safe, leading to low rates of AM, and is not associated with induced ischemia, increased mortality, and rehospitalization for heart failure at follow-up. Larger studies are needed to confirm our findings and to identify the optimal management strategy in this group of patients.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS1053077016304219.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
330.19 kB
Formato
Adobe PDF
|
330.19 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
